JP2014533243A5 - - Google Patents

Info

Publication number

JP2014533243A5

JP2014533243A5 JP2014539198A JP2014539198A JP2014533243A5 JP 2014533243 A5 JP2014533243 A5 JP 2014533243A5 JP 2014539198 A JP2014539198 A JP 2014539198A JP 2014539198 A JP2014539198 A JP 2014539198A JP 2014533243 A5 JP2014533243 A5 JP 2014533243A5

Authority

JP

Japan

Prior art keywords

amino acid

domain polypeptide

domain

acid modifications

construct

Prior art date

2012-11-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229920001184 polypeptide Polymers 0.000 claims description 145
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 145
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 145
• 229940024606 amino acid Drugs 0.000 claims description 130
• 150000001413 amino acids Chemical class 0.000 claims description 130
• 230000004048 modification Effects 0.000 claims description 123
• 238000012986 modification Methods 0.000 claims description 123
• 108060003951 Immunoglobulin Proteins 0.000 claims description 20
• 102000018358 immunoglobulin Human genes 0.000 claims description 20
• 239000000427 antigen Substances 0.000 claims description 9
• 102000036639 antigens Human genes 0.000 claims description 9
• 108091007433 antigens Proteins 0.000 claims description 9
• 238000002844 melting Methods 0.000 claims description 9
• 230000008018 melting Effects 0.000 claims description 9
• 229940099472 immunoglobulin a Drugs 0.000 claims description 6
• 238000000034 method Methods 0.000 claims description 6
• 230000001225 therapeutic effect Effects 0.000 claims description 6
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 229960005395 cetuximab Drugs 0.000 claims description 5
• 102000039446 nucleic acids Human genes 0.000 claims description 4
• 108020004707 nucleic acids Proteins 0.000 claims description 4
• 150000007523 nucleic acids Chemical class 0.000 claims description 4
• 229960003989 tocilizumab Drugs 0.000 claims description 4
• 208000026278 immune system disease Diseases 0.000 claims description 3
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 2
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
• 229960002964 adalimumab Drugs 0.000 claims description 2
• 229960000548 alemtuzumab Drugs 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 2
• 229960000598 infliximab Drugs 0.000 claims description 2
• 229960005386 ipilimumab Drugs 0.000 claims description 2
• 229960000310 isoleucine Drugs 0.000 claims description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
• 229960005108 mepolizumab Drugs 0.000 claims description 2
• 229930182817 methionine Natural products 0.000 claims description 2
• 229960001521 motavizumab Drugs 0.000 claims description 2
• 229960005027 natalizumab Drugs 0.000 claims description 2
• 229950010203 nimotuzumab Drugs 0.000 claims description 2
• 229950005751 ocrelizumab Drugs 0.000 claims description 2
• 229960002450 ofatumumab Drugs 0.000 claims description 2
• 229960000470 omalizumab Drugs 0.000 claims description 2
• 229960000402 palivizumab Drugs 0.000 claims description 2
• 229960001972 panitumumab Drugs 0.000 claims description 2
• 229960002087 pertuzumab Drugs 0.000 claims description 2
• 229960003876 ranibizumab Drugs 0.000 claims description 2
• 229960004641 rituximab Drugs 0.000 claims description 2
• 229960003824 ustekinumab Drugs 0.000 claims description 2
• 239000004474 valine Substances 0.000 claims description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 239000013604 expression vector Substances 0.000 claims 4
• 210000004962 mammalian cell Anatomy 0.000 claims 4
• 102000040430 polynucleotide Human genes 0.000 claims 3
• 108091033319 polynucleotide Proteins 0.000 claims 3
• 239000002157 polynucleotide Substances 0.000 claims 3
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
• 125000000539 amino acid group Chemical group 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000035475 disorder Diseases 0.000 claims 2
• 125000005842 heteroatom Chemical group 0.000 claims 2
• 208000015181 infectious disease Diseases 0.000 claims 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
• 230000004075 alteration Effects 0.000 claims 1
• 229950001863 bapineuzumab Drugs 0.000 claims 1
• 229960004669 basiliximab Drugs 0.000 claims 1
• 229960003270 belimumab Drugs 0.000 claims 1
• 229960000397 bevacizumab Drugs 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 229960003115 certolizumab pegol Drugs 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 229960002806 daclizumab Drugs 0.000 claims 1
• 229960001251 denosumab Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229960000284 efalizumab Drugs 0.000 claims 1
• 229950001109 galiximab Drugs 0.000 claims 1
• 229960000578 gemtuzumab Drugs 0.000 claims 1
• 229960001743 golimumab Drugs 0.000 claims 1
• 239000000833 heterodimer Substances 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 229960000575 trastuzumab Drugs 0.000 claims 1
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 230000003053 immunization Effects 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1